InvestorsHub Logo
Followers 4
Posts 790
Boards Moderated 0
Alias Born 09/22/2015

Re: None

Wednesday, 03/06/2019 11:55:17 PM

Wednesday, March 06, 2019 11:55:17 PM

Post# of 469800
Attractive Opportunities in the Infantile Spasms Therapeutics Market 2019-2024
Factors Driving the Growth of Infantile Spasms Therapeutics Market in Pharma & Healthcare Industry
avanti.dengale@arcognizance.com February 26, 2019 0 2 4 minutes read
Analytical Research Cognizance
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.

The global infantile spasms therapeutics market is growing at a slow pace. This is due to the increased availability of generic drugs and less approved therapies in the market and the less awareness of the disease and the available treatment options, especially in the low- and middle-income countries.
The classification of Infantile Spasms Therapeutics includes Oral, Injection. The proportion of Injection in 2016 is about 45%, and the proportion of Oral in 2016 is about 55%.

Based on application, the nitinol medical devices market is segmented into Hospital, Clinic and others. Clinic segment accounted for larger market share in terms of sales in 2016, Clinic segmented accounted for more than 45% of the market share in 2016.

United States is the largest consumption place, with a consumption market share nearly 83% in 2016. Following United States, Europe is the second largest consumption place with the consumption market share of 12.6% in 2016.

The US market is dominated by two approved products H.P. Acthar Gel (adrenocorticotropin hormone) and Sabril (vigabatrin). Sabril was the first drug to be approved by the Food and Drug Administration (FDA) in 2009 and H.P. Acthar Gel (adrenocorticotropin hormone) was approved for infantile spasms in 2010. Both have Orphan Drug Exclusivity (ODE) in the US.
In the future, the Infantile Spasms Therapeutics will have a good future; the price fluctuation has relationship with the raw material. The technology will more mature and the industry is more dispersion.

According to this study, over the next five years the Infantile Spasms Therapeutics market will register a 3.0% CAGR in terms of revenue, the global market size will reach US$ 150 million by 2024, from US$ 130 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Infantile Spasms Therapeutics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Infantile Spasms Therapeutics market by product type, application, key manufacturers and key regions and countries.

This study considers the Infantile Spasms Therapeutics value and volume generated from the sales of the following segments:

Request a sample of Infantile Spasms Therapeutics Market report @ http://www.arcognizance.com/enquiry-sample/268685

Segmentation by product type:
Oral
Injection

Segmentation by application:
Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Access this report of Infantile Spasms Therapeutics Market @ http://arcognizance.com/report/global-infantile-spasms-therapeutics-market-growth-2019-2024

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

The key manufacturers covered in this report:
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Infantile Spasms Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Infantile Spasms Therapeutics market by identifying its various subsegments.
Focuses on the key global Infantile Spasms Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Infantile Spasms Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Infantile Spasms Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Buy The Report @ http://www.arcognizance.com/purchase/268685

Major Point of TOC:

Chapter One: Scope of the Report

Chapter Two: Executive Summary

Chapter Three: Global Infantile Spasms Therapeutics by Players

Chapter Four: Infantile Spasms Therapeutics by Regions

Chapter Five: Americas

Chapter Six: APAC

Chapter Seven: Europe

Chapter Eight: Middle East & Africa

Chapter Nine: Market Drivers, Challenges and Trends

Chapter Ten: Marketing, Distributors and Customer

Chapter Eleven: Global Infantile Spasms Therapeutics Market Forecast

To Check Discount of Infantile Spasms Therapeutics Market @ http://www.arcognizance.com/discount/268685

About Us:
www.arcognizance.com is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics””based on the data collection facilities of big data, the face of “”business research facilities”” has changed drastically. With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the “”out of the box””developments in the market.

Contact US:
Name: Analytical research cognizance
Address: 100 Church Street,
8th floor, Manhattan,
New York 10007
Phone: +1 (646) 434-7969 +91 90967 44448
Email: enquiry@arcognizance.com
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News